Aas, M, Dazzan, P, Mondelli, V, Melle, I, Murray, RM, Pariante, CM (2014). A systematic review of cognitive function in first-episode psychosis, including a discussion on childhood trauma, stress, and inflammation. Frontiers in Psychiatry
Addington, D, Addington, J (1993). Assessing depression in schizophrenia: the Calgary Depression Scale. British Journal of Psychiatry
22 (Suppl.), 39–44.
American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders: DSM-IV, 4th edn.
American Psychiatric Association: Washington, DC.
Barder, HE, Sundet, K, Rund, BR, Evensen, J, Haahr, U, Ten Velden, HW, Joa, I, Johannessen, JO, Langeveld, H, Larsen, TK, Melle, I, Opjordsmoen, S, Rossberg, JI, Simonsen, E, Vaglum, P, McGlashan, T, Friis, S (2013). Neurocognitive development in first episode psychosis 5 years follow-up: associations between illness severity and cognitive course. Schizophrenia Research
Bilder, RM, Goldman, RS, Robinson, D, Reiter, G, Bell, L, Bates, JA, Pappadopulos, E, Willson, DF, Alvir, JM, Woerner, MG, Geisler, S, Kane, JM, Lieberman, JA (2000). Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. American Journal of Psychiatry
Birchwood, M, Smith, J, Drury, V, Healy, J, Macmillan, F, Slade, M (1994). A self-report Insight Scale for psychosis: reliability, validity and sensitivity to change. Acta Psychiatrica Scandinavica
Bowie, CR, Leung, WW, Reichenberg, A, McClure, MM, Patterson, TL, Heaton, RK, Harvey, PD (2008). Predicting schizophrenia patients’ real-world behavior with specific neuropsychological and functional capacity measures. Biological Psychiatry
Bozikas, VP, Andreou, C (2011). Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature. Australian and New Zealand Journal of Psychiatry
Buchanan, RW, Keefe, RS, Umbricht, D, Green, MF, Laughren, T, Marder, SR (2011). The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?
Cannon-Spoor, HE, Potkin, SG, Wyatt, RJ (1982). Measurement of premorbid adjustment in chronic schizophrenia. Schizophrenia Bulletin
Chen, EY, Hui, CL, Dunn, EL, Miao, MY, Yeung, WS, Wong, CK, Chan, WF, Tang, WN (2005). A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients. Schizophrenia Research
Cohen, J (1988). Statistical Power Analysis for the Behavioural Sciences. Lawrence Erlbaum Associates: Hillsdale, NJ.
Davidson, M, Galderisi, S, Weiser, M, Werbeloff, N, Fleischhacker, WW, Keefe, RS, Boter, H, Keet, IP, Prelipceanu, D, Rybakowski, JK, Libiger, J, Hummer, M, Dollfus, S, Lopez-Ibor, JJ, Hranov, LG, Gaebel, W, Peuskens, J, Lindefors, N, Riecher-Rossler, A, Kahn, RS (2009). Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). American Journal of Psychiatry
de Wit, H (2010). Flupenthixol. In Encyclopedia of Psychopharmacology: Springer Reference (ed. Stolerman, I. and Rice, L.), pp. 538–539. Springer-Verlag: Berlin Heidelberg.
Desamericq, G, Schurhoff, F, Meary, A, Szoke, A, Macquin-Mavier, I, Bachoud-Levi, AC, Maison, P (2014). Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. European Journal of Clinical Pharmacology
Dickinson, D, Ragland, JD, Gold, JM, Gur, RC (2008). General and specific cognitive deficits in schizophrenia: Goliath defeats David?
Ekerholm, M, Firus, WS, Fagerberg, T, Soderman, E, Terenius, L, Agartz, I, Jonsson, EG, Nyman, H (2012). Neurocognitive function in long-term treated schizophrenia: a five-year follow-up study. Psychiatry Research
Emsley, R, Rabinowitz, J, Torreman, M (2003). The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. Schizophrenia Research
First, MB, Spitzer, RLGM, Williams, LBW (1994). Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P). New York State Psychiatric Institute, Biometrics Research: New York.
Goldberg, TE, Goldman, RS, Burdick, KE, Malhotra, AK, Lencz, T, Patel, RC, Woerner, MG, Schooler, NR, Kane, JM, Robinson, DG (2007). Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
Archive of General Psychiatry
Goldberg, TE, Keefe, RS, Goldman, RS, Robinson, DG, Harvey, PD (2010). Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology
Harvey, PD, Rabinowitz, J, Eerdekens, M, Davidson, M (2005). Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. American Journal of Psychiatry
International Conference on Harmonization (1996). ICH Harmonized Tripartite Guidelines for Good Clinical Practice. Brookwood Medical Publications Ltd: Richmond, Surrey.
Kahn, RS, Keefe, RS (2013). Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psychiatry
Kay, SR, Fizbein, A, Opler, LA (1987). The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophrenia Bulletin
Keefe, RS, Bilder, RM, Davis, SM, Harvey, PD, Palmer, BW, Gold, JM, Meltzer, HY, Green, MF, Capuano, G, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, Davis, CE, Hsiao, JK, Lieberman, JA (2007a). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Archives of General Psychiatry
Keefe, RS, Buchanan, RW, Marder, SR, Schooler, NR, Dugar, A, Zivkov, M, Stewart, M (2013). Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?
Keefe, RS, Seidman, LJ, Christensen, BK, Hamer, RM, Sharma, T, Sitskoorn, MM, Lewine, RR, Yurgelun-Todd, DA, Gur, RC, Tohen, M, Tollefson, GD, Sanger, TM, Lieberman, JA (2004). Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. American Journal of Psychiatry
Keefe, RS, Seidman, LJ, Christensen, BK, Hamer, RM, Sharma, T, Sitskoorn, MM, Rock, SL, Woolson, S, Tohen, M, Tollefson, GD, Sanger, TM, Lieberman, JA (2006). Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biological Psychiatry
Keefe, RS, Silva, SG, Perkins, DO, Lieberman, JA (1999). The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophrenia Bulletin
Keefe, RS, Sweeney, JA, Gu, H, Hamer, RM, Perkins, DO, McEvoy, JP, Lieberman, JA (2007b). Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. American Journal of Psychiatry
Lieberman, JA, Perkins, DO, Jarskog, LF (2007). Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia. CNS Spectrums
Mishara, AL, Goldberg, TE (2004). A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biological Psychiatry
Nielsen, RE (2011). Cognition in schizophrenia – a systematic review. Drug Discovery Today: Therapeutic Strategies
Nuechterlein, KH, Green, MF (2006). MATRICS Consensus Battery Manual. MATRICS Assessment Inc.: Los Angeles.
Nuechterlein, KH, Green, MF, Kern, RS, Baade, LE, Barch, DM, Cohen, JD, Essock, S, Fenton, WS, Frese III, FJ, Gold, JM, Goldberg, T, Heaton, RK, Keefe, RS, Kraemer, H, Mesholam-Gately, R, Seidman, LJ, Stover, E, Weinberger, DR, Young, AS, Zalcman, S, Marder, SR (2008). The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. American Journal of Psychiatry
Nuechterlein, KH, Subotnik, KL, Green, MF, Ventura, J, Asarnow, RF, Gitlin, MJ, Yee, CM, Gretchen-Doorly, D, Mintz, J (2011). Neurocognitive predictors of work outcome in recent-onset schizophrenia. Schizophrenia Bulletin
37 (Suppl. 2), S33–S40.
Porter, RJ, Bowie, CR, Jordan, J, Malhi, GS (2013). Cognitive remediation as a treatment for major depression: a rationale, review of evidence and recommendations for future research. Australian and New Zealand Journal of Psychiatry
Rajji, TK, Voineskos, AN, Butters, MA, Miranda, D, Arenovich, T, Menon, M, Ismail, Z, Kern, RS, Mulsant, BH (2013). Cognitive performance of individuals with schizophrenia across seven decades: a study using the MATRICS Consensus Cognitive Battery. American Journal of Geriatric Psychiatry
Shen, X, Xia, J, Adams, CE (2012). Flupenthixol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews
2012, Issue 11. Art. No.: CD009777. DOI: 10.1002/14651858.CD009777.pub2.
Stern, R, White, T (2003). Neuropsychological Assessment Battery: Mazes. Psychological Assessment Resources, Incorporated: Lutz, FL.
Stip, E, Chouinard, S, Boulay, LJ (2005). On the trail of a cognitive enhancer for the treatment of schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry
Tandon, R, Nasrallah, HA, Keshavan, MS (2009). Schizophrenia, “just the facts” 4. Clinical features and conceptualization. Schizophrenia Research
Woodberry, KA, McFarlane, WR, Giuliano, AJ, Verdi, MB, Cook, WL, Faraone, SV, Seidman, LJ (2013). Change in neuropsychological functioning over one year in youth at clinical high risk for psychosis. Schizophrenia Research
Woodward, ND, Purdon, SE, Meltzer, HY, Zald, DH (2007). A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophrenia Research
World Health Organization (1998). Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychological Medicine